Our global subject matter experts operate as one integrated, accessible team to solve your challenges faster. From drug substance, drug product, and clinical trial research and manufacturing to clinical supply optimization, we combine proven end-to-end capabilities and state-of-the-art technologies with dedicated team members from across our organization who share your mission to help patients and improve healthcare. Using the strength of our global network, we’re working to simplify and accelerate the drug development process to get you to the clinic — and to market — quicker.
Integrated timelines, joint project, management, and streamlined information sharing
Personalized planning and transparency across supply chains
Global networks with regional expertise for scale-up across geographies
Now providing fully integrated CDMO and CRO services, Thermo Fisher Scientific offers a comprehensive suite of world-class solutions across the clinical development spectrum — from scientific discovery to assessing safety, efficacy, and healthcare outcomes, to managing clinical trial logistics, to the development and manufacturing of the final drug product.
We deliver flexible solutions to meet your individual needs:
Our Patheon™ Quick to Care™ program is designed to streamline your drug substance and drug product development, demand planning, and clinical trial supply execution into a single customized solution. We help you simplify your supply chain and accelerate drug development with a seamless, one-team approach. While coordinating with multiple vendors exhausts valuable time and resources, this single-vendor solution offers benefits across the continuum, including:
Now more than ever, you’re asked to do more in less time. Our Patheon™ Quick to Clinic™ program is our speed-focused solution, built for small and large molecule drug development as well as viral vector services. Quick to Clinic™ is designed to accelerate early development while using a proven process platform, ensuring that critical details aren’t overlooked.
How do we do it?
Partnering with small pharma and emerging biopharma
We work on an average of 27 new biologic programs per year, with 63% of those projects for monoclonal antibodies.
With our breadth of experience, scientific expertise, and globally integrated network, we provide you with a customizable solution to reduce your development timeline. We apply a science-driven, risk-based approach to every step of the development and manufacturing process, while providing you with a global footprint and the scientific and therapeutic expertise to ensure your discovery makes it to the patients who need it most. We have one shared commitment—your drug development success.